Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 1 Baseline characteristics at the start of first TNF inhibitor

From: Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis

Parameter n = 624 All Patients
n = 624
BMI category
Normal
n = 332
Overweight
n = 204
Obese
n = 88
BMI 624 25.4 (4.3) 22.3 (1.7) 27.0 (1.4)* 33.2 (3.2)* #
Male sex, % 624 62.2 55.7 73.5* 60.2
mNYc positive, % 437 73.9 73.1 75.2 74.1
Age, years 624 39.4 (11.6) 37.4 (11.3) 41.1 (11.7)* 43.2 (10.5)*
Symptom duration, years 619 13.0 (10.9) 12.2 (10.3) 13.6 (11.7) 14.5 (11.0)
HLA-B27 positive, % 571 78.1 80.5 77.2 70.9
BASDAI 549 5.5 (1.9) 5.3 (2.0) 5.6 (1.9) 6.1 (1.7)*
 BASDAI Question 1 556 6.0 (2.3) 5.8 (2.3) 6.1 (2.2) 6.1 (2.0)
 BASDAI Question 2 555 6.7 (2.3) 6.5 (2.4) 6.9 (2.2) 7.0 (2.1)
 BASDAI Question 3 553 4.2 (3.0) 3.9 (3.0) 4.4 (3.0) 5.4 (2.8)*
 BASDAI Question 4 556 5.2 (3.0) 5.1 (3.1) 5.2 (3.0) 5.8 (2.9)
 BASDAI Question 5 554 6.1 (2.7) 5.9 (2.7) 6.3 (2.5) 6.6 (2.8)
 BASDAI Question 6 554 4.9 (2.9) 4.9 (3.0) 4.8 (2.8) 5.3 (2.7)
Patient GA 552 6.4 (2.3) 6.2 (2.5) 6.6 (2.2) 6.6 (2.0)
Physician GA 600 4.9 (1.9) 4.9 (1.8) 4.9 (1.8) 5.2 (2.0)
ASDAS 517 3.5 (0.9) 3.4 (0.9) 3.5 (0.9) 3.7 (0.9)
CRP (mg/l) 584 15.1 (20.0) 15.3 (19.0) 14.0 (20.1) 16.9 (23.4)
Elevated CRP, % 581 53.4 54.8 50.0 55.4
BASFI 555 4.1 (2.5) 3.7 (2.4) 4.2 (2.4) 5.0 (2.6)*
BASMI, median (IQR) 540 2 (1–3) 2 (1–3) 2 (1–3) 2 (1–4)
EQ-5D 540 56.2 (20.9) 58.3 (20.7) 54.7 (20.8) 51.8 (21.2)*
Peripheral arthritis, % 606 34.2 32.9 35.9 34.9
Current enthesitis, % 605 71.9 69.1 71.7 82.8
Modified MASES, median (IQR) 599 2 (0–4) 1 (0–4) 2 (0–4) 4 (2–6)*#
Dactylitis ever, % 616 10.2 8.3 12.2 12.9
Uveitis ever, % 555 22.2 26.4 17.4 17.7
Psoriasis ever, % 478 12.3 13.0 10.6 14.3
Current smokers, % 527 36.4 39.2 31.2 38.2
Education, high, % 594 84.0 86.8 81.9 78.0
Exercise score, median (IQR) 500 2.0 (0.0–4.0) 2.0 (0.0–4.0) 2.0 (0.0–3.0) 1.5 (0.0–3.0)
On NSAIDs, % 565 92.2 92.8 91.6 91.4
On DMARDs, % 624 12.5 11.2 13.2 15.9
On steroids, % 624 9.5 10.2 7.8 10.2
First TNFi used 624     
Adalimumab, %   34.5 35.8 36.3 25.0
Certolizumab, %   <0.1 0.3 1.0 0.0
Etanercept, %   26.7 24.4 28.9 28.4
Golimumab, %   16.9 17.2 14.2 21.6
Infliximab, %   21.9 22.3 19.6 25.0
  1. Except where indicated otherwise, values are the mean (SD)
  2. Significance levels of two-group comparisons are Bonferroni-corrected: *p < 0.015 compared with patients of normal weight; # p <0 .015 compared with patients who are overweight
  3. Exercise score refers to the number of exercise sessions per week
  4. Normal weight = BMI 18.5–25; overweight = BMI 25–30; obese = BMI >30
  5. ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, BMI body mass index, CRP C-reactive peptide, DMARDs disease-modifying antirheumatic drugs, EQ-5D EuroQol 5-domain, GA global assessment, HLA-B27 human leucocyte antigen-B27, IQR interquartile range, MASES Maastricht Ankylosing Spondylitis Enthesitis Score (modification refers to the inclusion of the plantar fascia in the count), mNYc modified New York criteria, NSAIDs nonsteroidal anti-inflammatory drugs, TNFi tumor necrosis factor inhibitor